Depomed granted Ironwood non-exclusive worldwide rights to use Depomed's Acuform gastric retentive formulation technology to develop compound for gastrointestinal disorders

Depomed Inc.

U.S. / Small-Cap Biopharma (<$1 billion)

$408.7m on 07/29/2011 [market cap]

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Ironwood Pharmaceuticals Inc.

U.S. / Mid-Cap Biopharma ($1-$50 billion)

$1,490.1m on 07/29/2011 [market cap]

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced